Geron Initiates Clinical Trial Of GRN163L In Combination With Paclitaxel And Bevacizu
Geron Corporation (Nasdaq: GERN) announced the enrollment of the first patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in locally recurrent or metastatic breast cancer. The primary objective of the Phase I/II, dose escalation study is to determine the safety, maximum tolerated dose (MTD) and objective response rate of GRN163L when administered intravenously in combination with a paclitaxel/bevacizumab regimen in this patient population.
More... |
Thanks for posting.
|
All times are GMT -7. The time now is 03:49 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021